- Conditions
- Child Disruptive Behavior Disorders, Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Triple P Online System, Placebo Comparator
- Other · Behavioral
- Lead sponsor
- Oregon Research Institute
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Eugene, Oregon • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 141
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Preterm Birth
- Interventions
- 17-alpha-hydroxyprogesterone caproate injectable, Placebo
- Drug
- Lead sponsor
- Obstetrix Medical Group
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Laguna Hills, California + 13 more
- Conditions
- Anterior Cruciate Ligament Tear
- Interventions
- anakinra (150mg), Saline intraarticularly
- Drug · Other
- Lead sponsor
- Cale Jacobs, PhD
- Other
- Eligibility
- 14 Years to 40 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- ADHD - Inattentive Type, ADHD - Combined Type
- Interventions
- OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 7 Years to 11 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Breast Cancer, Metastatic Triple-Negative Breast Cancer
- Interventions
- Eribulin, SDX-7320, Placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more
- Conditions
- Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Pain, Postoperative, Opioid Use, Knee Osteoarthritis
- Interventions
- cannabidiol, Ora-sweet SF
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mild Traumatic Brain Injury, Post Traumatic Stress Disorder
- Interventions
- of Lactobacillus reuteri (L. reuteri; DSM 17938), Sunflower and medium chain triglyceride oils
- Dietary Supplement · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction
- Interventions
- ProstaThrive™ Supplement, Placebo
- Dietary Supplement
- Lead sponsor
- Optimale
- Industry
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Breast Cancer
- Interventions
- Enzalutamide, Placebo, Paclitaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 6
- States / cities
- Topeka, Kansas • Metairie, Louisiana • The Bronx, New York + 3 more
- Conditions
- MRSA
- Interventions
- Retapamulin, Placebo Ointment
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 9 Months to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cystic Fibrosis
- Interventions
- TEZ, IVA, VX-440, Matched Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-659/TEZ/IVA, TEZ/IVA, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 107
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Bupivacaine liposome, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Eau Claire, Wisconsin
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-Paclitaxel, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Oakland, California + 42 more
- Conditions
- Advanced and Metastatic Breast Cancer
- Interventions
- AZD2014, Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 5
- States / cities
- Encinitas, California • Sarasota, Florida • Detroit, Michigan + 2 more
- Conditions
- Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
- Interventions
- Artemisia Annua Leaf, placebo
- Dietary Supplement · Other
- Lead sponsor
- National University of Natural Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Postoperative Nausea and Vomiting (PONV), Nausea
- Interventions
- Aprepitant, Ondansetron, Promethazine, Dexamethasone
- Drug
- Lead sponsor
- Sergio Bergese
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more
- Conditions
- Hair Thinning, Facial Skin Texture, Skin Ageing
- Interventions
- Biotin and silicon, Placebo
- Dietary Supplement
- Lead sponsor
- Nutrition 21, Inc.
- Industry
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Pelvic Pain, IUD
- Interventions
- Ibuprofen, Placebos
- Drug
- Lead sponsor
- Orlando VA Medical Center
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
- Interventions
- Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-152, TEZ/IVA, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more